At the news
? NEUTRALIMPACT 4/10 8-K filed May 7, 2026 at 09:20 ET
Edgewise Therapeutics reported Q1 2026 net loss per share of $0.46, beating consensus of -$0.48 by ~4.2%. The pre-revenue biotech highlighted positive long-term sevasemten stabilization data and reiterated key catalysts (CIRRUS-HCM 12-week data in Q2 2026, GRAND CANYON pivotal results in Q4 2026). Cash decreased to $499.6M, with R&D spending up YoY as pipeline programs advanced.
- Net loss per share $0.46 vs consensus $0.48 beat (5.2% surprise)
- Cash, cash equivalents and marketable securities $499.6M as of March 31, 2026
- R&D expenses $42.7M (up from $36.8M in Q1 2025) due to increased EDG-7500 and EDG-15400 activity
- Net loss widened to $49.0M from $40.8M in Q1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access